Does the media prefer TBPH or ARQT?

In the previous week, Theravance Biopharma had 1 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 2 mentions for Theravance Biopharma and 1 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.42 beat Theravance Biopharma's score of 0.15 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Theravance Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcutis Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TBPH or TARS?

In the previous week, Tarsus Pharmaceuticals had 3 more articles in the media than Theravance Biopharma. MarketBeat recorded 5 mentions for Tarsus Pharmaceuticals and 2 mentions for Theravance Biopharma. Tarsus Pharmaceuticals' average media sentiment score of 0.33 beat Theravance Biopharma's score of 0.15 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Theravance Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tarsus Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer RGC or TBPH?

Theravance Biopharma has a consensus price target of $19.40, suggesting a potential upside of 13.92%. Given Theravance Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Theravance Biopharma is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Theravance Biopharma 0 Sell rating(s) 8 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, RGC or TBPH?

Theravance Biopharma has higher revenue and earnings than Regencell Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Theravance Biopharma $104.31M 8.48 $105.89M $1.01 16.86

Does the media prefer RGC or TBPH?

In the previous week, Theravance Biopharma had 1 more articles in the media than Regencell Bioscience. MarketBeat recorded 2 mentions for Theravance Biopharma and 1 mentions for Regencell Bioscience. Theravance Biopharma's average media sentiment score of 0.15 beat Regencell Bioscience's score of 0.00 indicating that Theravance Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Theravance Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TBPH or MBX?

In the previous week, MBX Biosciences had 3 more articles in the media than Theravance Biopharma. MarketBeat recorded 5 mentions for MBX Biosciences and 2 mentions for Theravance Biopharma. MBX Biosciences' average media sentiment score of 0.24 beat Theravance Biopharma's score of 0.15 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Theravance Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate MOR or TBPH?

Theravance Biopharma has a consensus price target of $19.40, indicating a potential upside of 13.92%. Given Theravance Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Theravance Biopharma is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Theravance Biopharma 0 Sell rating(s) 8 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Theravance Biopharma (TBPH) Competitors

$17.03 0.00 (0.00%)

As of 10/1/2026

Compare

TBPH vs. ARQT, TARS, RGC, MBX, and MOR

Should you buy Theravance Biopharma stock or one of its competitors? Theravance Biopharma's main competitors and comparable companies include Arcutis Biotherapeutics (ARQT), Tarsus Pharmaceuticals (TARS), Regencell Bioscience (RGC), MBX Biosciences (MBX), and MorphoSys (MOR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Theravance Biopharma compare to Arcutis Biotherapeutics?

Theravance Biopharma (NASDAQ:TBPH) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

Theravance Biopharma has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market.

99.1% of Theravance Biopharma shares are held by institutional investors. 7.7% of Theravance Biopharma shares are held by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Theravance Biopharma has higher earnings, but lower revenue than Arcutis Biotherapeutics. Theravance Biopharma is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$104.31M	8.48	$105.89M	$1.01	16.86
Arcutis Biotherapeutics	$376.07M	8.47	-$16.14M	$0.21	120.71

In the previous week, Theravance Biopharma had 1 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 2 mentions for Theravance Biopharma and 1 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.42 beat Theravance Biopharma's score of 0.15 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Theravance Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcutis Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Theravance Biopharma has a net margin of 51.58% compared to Arcutis Biotherapeutics' net margin of 6.15%. Arcutis Biotherapeutics' return on equity of 15.05% beat Theravance Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	51.58%	-0.77%	-0.46%
Arcutis Biotherapeutics	6.15%	15.05%	6.51%

Theravance Biopharma presently has a consensus target price of $19.40, indicating a potential upside of 13.92%. Arcutis Biotherapeutics has a consensus target price of $35.57, indicating a potential upside of 40.32%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Arcutis Biotherapeutics beats Theravance Biopharma on 10 of the 16 factors compared between the two stocks.

How does Theravance Biopharma compare to Tarsus Pharmaceuticals?

Theravance Biopharma (NASDAQ:TBPH) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Theravance Biopharma has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$104.31M	8.48	$105.89M	$1.01	16.86
Tarsus Pharmaceuticals	$451.36M	7.18	-$66.42M	-$1.09	N/A

Theravance Biopharma has a net margin of 51.58% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Theravance Biopharma's return on equity of -0.77% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	51.58%	-0.77%	-0.46%
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%

Theravance Biopharma has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market.

In the previous week, Tarsus Pharmaceuticals had 3 more articles in the media than Theravance Biopharma. MarketBeat recorded 5 mentions for Tarsus Pharmaceuticals and 2 mentions for Theravance Biopharma. Tarsus Pharmaceuticals' average media sentiment score of 0.33 beat Theravance Biopharma's score of 0.15 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Theravance Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tarsus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Theravance Biopharma presently has a consensus price target of $19.40, indicating a potential upside of 13.92%. Tarsus Pharmaceuticals has a consensus price target of $100.86, indicating a potential upside of 36.52%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tarsus Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

99.1% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 7.7% of Theravance Biopharma shares are owned by company insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Tarsus Pharmaceuticals beats Theravance Biopharma on 9 of the 17 factors compared between the two stocks.

How does Theravance Biopharma compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Theravance Biopharma (NASDAQ:TBPH) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

Theravance Biopharma has a consensus price target of $19.40, suggesting a potential upside of 13.92%. Given Theravance Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Theravance Biopharma is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by insiders. Comparatively, 7.7% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Theravance Biopharma has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Theravance Biopharma	$104.31M	8.48	$105.89M	$1.01	16.86

Theravance Biopharma has a net margin of 51.58% compared to Regencell Bioscience's net margin of 0.00%. Regencell Bioscience's return on equity of 0.00% beat Theravance Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Theravance Biopharma	51.58%	-0.77%	-0.46%

In the previous week, Theravance Biopharma had 1 more articles in the media than Regencell Bioscience. MarketBeat recorded 2 mentions for Theravance Biopharma and 1 mentions for Regencell Bioscience. Theravance Biopharma's average media sentiment score of 0.15 beat Regencell Bioscience's score of 0.00 indicating that Theravance Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Theravance Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Regencell Bioscience has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

Summary

Theravance Biopharma beats Regencell Bioscience on 9 of the 12 factors compared between the two stocks.

How does Theravance Biopharma compare to MBX Biosciences?

Theravance Biopharma (NASDAQ:TBPH) and MBX Biosciences (NASDAQ:MBX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Theravance Biopharma currently has a consensus price target of $19.40, suggesting a potential upside of 13.92%. MBX Biosciences has a consensus price target of $83.89, suggesting a potential upside of 42.28%. Given MBX Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe MBX Biosciences is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

Theravance Biopharma has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$104.31M	8.48	$105.89M	$1.01	16.86
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

In the previous week, MBX Biosciences had 3 more articles in the media than Theravance Biopharma. MarketBeat recorded 5 mentions for MBX Biosciences and 2 mentions for Theravance Biopharma. MBX Biosciences' average media sentiment score of 0.24 beat Theravance Biopharma's score of 0.15 indicating that MBX Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Theravance Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Theravance Biopharma has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.1, indicating that its stock price is 90% less volatile than the broader market.

99.1% of Theravance Biopharma shares are held by institutional investors. 7.7% of Theravance Biopharma shares are held by insiders. Comparatively, 31.1% of MBX Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Theravance Biopharma has a net margin of 51.58% compared to MBX Biosciences' net margin of 0.00%. Theravance Biopharma's return on equity of -0.77% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	51.58%	-0.77%	-0.46%
MBX Biosciences	N/A	-26.02%	-24.94%

Summary

Theravance Biopharma beats MBX Biosciences on 9 of the 16 factors compared between the two stocks.

How does Theravance Biopharma compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Theravance Biopharma (NASDAQ:TBPH) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

MorphoSys has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

Theravance Biopharma has a consensus price target of $19.40, indicating a potential upside of 13.92%. Given Theravance Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Theravance Biopharma is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Theravance Biopharma had 2 more articles in the media than MorphoSys. MarketBeat recorded 2 mentions for Theravance Biopharma and 0 mentions for MorphoSys. Theravance Biopharma's average media sentiment score of 0.15 beat MorphoSys' score of 0.00 indicating that Theravance Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
MorphoSys	Neutral
Theravance Biopharma	Neutral

Theravance Biopharma has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Theravance Biopharma	$104.31M	8.48	$105.89M	$1.01	16.86

18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 7.7% of Theravance Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Theravance Biopharma has a net margin of 51.58% compared to MorphoSys' net margin of -226.79%. Theravance Biopharma's return on equity of -0.77% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Theravance Biopharma	51.58%	-0.77%	-0.46%

Summary

Theravance Biopharma beats MorphoSys on 12 of the 15 factors compared between the two stocks.

Get Theravance Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TBPH vs. The Competition

Export

Metric	Theravance Biopharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$884.18M	$12.27B	$7.14B	$13.10B
Dividend Yield	N/A	2.64%	2.54%	16.76%
P/E Ratio	16.86	655.04	214.49	21.54
Price / Sales	8.48	749.22	607.75	91.81
Price / Cash	N/A	82.26	77.60	51.75
Price / Book	2.91	10.46	10.92	6.30
Net Income	$105.89M	$2.83B	$3.50B	$361.43M
7 Day Performance	N/A	-1.65%	-2.11%	-1.67%
1 Month Performance	-0.23%	-5.77%	-6.34%	-3.94%
1 Year Performance	21.04%	-3.80%	8.81%	2.77%

Theravance Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TBPH Theravance Biopharma	2.0824 of 5 stars	$17.03 flat	$19.40 +13.9%	N/A	$884.18M	$104.31M	16.86	110
ARQT Arcutis Biotherapeutics	3.8194 of 5 stars	$27.42 +5.6%	$35.57 +29.7%	+28.0%	$3.45B	$376.07M	130.56	354
TARS Tarsus Pharmaceuticals	3.1793 of 5 stars	$78.05 +0.8%	$94.00 +20.4%	+31.6%	$3.42B	$451.36M	N/A	50
RGC Regencell Bioscience	0.2791 of 5 stars	$6.15 +3.8%	N/A	-60.0%	$3.04B	N/A	N/A	10	News Coverage
MBX MBX Biosciences	2.6495 of 5 stars	$61.81 +1.4%	$77.00 +24.6%	+215.9%	$2.98B	N/A	N/A	63	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TBPH) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Theravance Biopharma (TBPH) Competitors

TBPH vs. ARQT, TARS, RGC, MBX, and MOR

How does Theravance Biopharma compare to Arcutis Biotherapeutics?

Summary

How does Theravance Biopharma compare to Tarsus Pharmaceuticals?

Summary

How does Theravance Biopharma compare to Regencell Bioscience?

Summary

How does Theravance Biopharma compare to MBX Biosciences?

Summary

How does Theravance Biopharma compare to MorphoSys?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBPH vs. The Competition

Theravance Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Theravance Biopharma (TBPH) Competitors

TBPH vs. ARQT, TARS, RGC, MBX, and MOR

How does Theravance Biopharma compare to Arcutis Biotherapeutics?

Which has more volatility and risk, TBPH or ARQT?

Do institutionals & insiders hold more shares of TBPH or ARQT?

Which has higher valuation & earnings, TBPH or ARQT?

Does the media prefer TBPH or ARQT?

Is TBPH or ARQT more profitable?

Do analysts recommend TBPH or ARQT?

Summary

How does Theravance Biopharma compare to Tarsus Pharmaceuticals?

Which has stronger earnings and valuation, TBPH or TARS?

Is TBPH or TARS more profitable?

Which has more risk & volatility, TBPH or TARS?

Does the media refer more to TBPH or TARS?

Do analysts recommend TBPH or TARS?

Do institutionals & insiders have more ownership in TBPH or TARS?

Summary

How does Theravance Biopharma compare to Regencell Bioscience?

Do analysts prefer RGC or TBPH?

Do institutionals and insiders hold more shares of RGC or TBPH?

Which has better earnings & valuation, RGC or TBPH?

Is RGC or TBPH more profitable?

Does the media prefer RGC or TBPH?

Which has more volatility & risk, RGC or TBPH?

Summary

How does Theravance Biopharma compare to MBX Biosciences?

Do analysts rate TBPH or MBX?

Which has higher earnings and valuation, TBPH or MBX?

Does the media favor TBPH or MBX?

Which has more risk & volatility, TBPH or MBX?

Do institutionals and insiders believe in TBPH or MBX?

Is TBPH or MBX more profitable?

Summary

How does Theravance Biopharma compare to MorphoSys?

Which has more risk & volatility, MOR or TBPH?

Do analysts rate MOR or TBPH?

Does the media favor MOR or TBPH?

Which has stronger valuation and earnings, MOR or TBPH?

Do institutionals and insiders believe in MOR or TBPH?

Is MOR or TBPH more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBPH vs. The Competition

Theravance Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools